Bispecific T cell Engagers Virtual Workshop

Sept. 30–Oct. 1, 2021 • Online

View Schedule • Registration Rates • Register Now

ORGANIZERS

• Elizabeth Budde, MD, PhD – City of Hope
• Daniel S. Chen, MD, PhD
• James L. Gulley, MD, PhD, FACP – National Cancer Institute

Overview

The safety of our attendees at our in-person events is of the utmost importance at the Society for Immunotherapy of Cancer (SITC). Given the recent increase in the COVID-19 virus and the desire to keep everyone as safe as possible, the Bispecific T cell Engagers Workshop, Sept. 30-Oct.1 2021 will now be held virtually.

SITC invites you to attend the workshop, Bispecific T cell Engagers Virtual Workshop. This workshop will focus on T cell engager biology and therapeutic strategies including target selection, therapeutic engineering and design features, cytotoxicity vs cytokine release, impact of the tumor microenvironment, and advances in conditionally-active binding.

Additionally, considerations related to dosing, schedule, sequencing and combination approaches for optimizing both endogenous and synthetic immunity will be discussed.

The virtual format assures a compelling program that can be held safely and successfully, and allows us to accommodate as many participants as possible.

To thank you for your continued interest in this workshop, we are happy to be able to offer a 50 percent discount on the registration rate. Register today at the special new rate!

Target Audience

• Basic, translational and clinical researchers from academic, industry, or government settings with an interest in developing, validating and applying T cell engager therapies for cancer treatment.

Learning Objectives

• Compare and contrast cancer immunotherapy approaches employing endogenous or synthetic immunity.
• Describe the biological and engineering considerations for development of T cell engagers.
• Outline current clinical application of T cell engagers and identify challenges with their use in cancer immunotherapy.

Immediately preceding the Bispecific T cell Engagers Virtual Workshop, SITC is hosting an innovative workshop, Interrogating the Tumor-Specific Surfaceome for Immune Targeting, focused on the tumor cell surfaceome and the many opportunities that accompany it for the development of future immunotherapies and maximization of existing techniques.

A collaborative session, taking place the morning of Sept. 30, will allow attendees from both workshops to discuss alignment and debates in the areas of the two workshops with the focus on how to continue to advance the field.

It is anticipated that the efforts of these workshops will fuel innovative collaborations, disseminate important knowledge to the rest of the immunotherapy field, and help assure the continued growth of immunotherapy treatments as a whole.

Participants will receive a discount when registering for both the Bispecific T cell Engagers Workshop and the Surfaceome Workshop.

View Program Schedule

Registrants will receive a link to access the virtual platform before the program.

The Bispecific T cell Engagers Workshop is supported, in part, by educational grants from Amgen Inc., Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US, Inc. and Pfizer, Inc. (as of 09/23/2021).

If you have questions about this program, please contact the SITC Education team.